Pliant’s lead program, PLN-74809, is a small-molecule, dual selective inhibitor of αVβ1 / αVβ6 for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). These integrins cause upstream activation of TGF-β1 in actively fibrotic tissue. Inhibition of these integrins will block TGF-β1 activation, thereby preventing the growth of fibrotic tissue within the lung and bile ducts. PLN-74809 is being evaluated in Phase 2a trials in patients with IPF.
Pliant’s second program, PLN-1474, is an oral, small-molecule, selective inhibitor of TGF-ß activation by the integrin αVβ1 for the treatment of end-stage liver fibrosis in NASH. Clinical testing is anticipated to start in 2020.